Replies to post #208330 on Biotech Values

[DewDiligence]

XON’s 12/31/16 pro forma cash was $218.2M; this consists of $243.2M on the balance sheet at 12/31/16, less $25.0 paid for AQB shares purchased on 1/5/17 (#msg-128099078):

http://finance.yahoo.com/news/intrexon-announces-fourth-quarter-full-221000061.html

[DewDiligence]

AQB has two major shareholders (as of 4/6/19):

https://www.sec.gov/Archives/edgar/data/1603978/000160397817000010/a2017proxystatement.htm (page 16)

• XON 68.6% stake
• ABT 8.3% stake

The total number of basic shares outstanding is 8.88M, which is unchanged since XON’s purchase of 2.42M shares in Jan 2017 (#msg-128099078).